```
-> b reg
FILE 'REGISTRY' ENTERED AT 11:19:02 ON 15 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 SEP 2008  HIGHEST RN 1049627-95-3
DICTIONARY FILE UPDATES:  14 SEP 2008  HIGHEST RN 1049627-95-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

-> d que sta l15
L7              STR
```




```
VAR G1=O/S
REP G2=(0-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
L9            9009 SEA FILE=REGISTRY SSS FUL L7
L13             STR
```




```
VAR G1=O/S
REP G2=(0-2) C
REP G3=(0-4) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E4 C  E2 N  AT  17

GRAPH ATTRIBUTES:
```

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L15 42 SEA FILE=REGISTRY SUB=L9 SSS FUL L13

100.0% PROCESSED 461 ITERATIONS 42 ANSWERS
SEARCH TIME: 00.00.01

-> b hcap
FILE 'HCAPLUS' ENTERED AT 11:19:12 ON 15 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Sep 2008 VOL 149 ISS 12
FILE LAST UPDATED: 14 Sep 2008 (20080914/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

-> d bib abs hitrn fhitstr l18 tot

L18 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:128596 HCAPLUS

DN 148:369264

TI Novel water-soluble sedative-hypnotic agents isoindolin-1-one derivatives

AU Kanamitsu, Norimasa; Osaki, Takashi; Itsuji, Yutaka; Yoshimura, Masakazu; Tsujimoto, Hisashi; Soga, Manabu

CS Central Research Laboratory, Maruishi Pharmaceutical Co., Ltd., 2-2-18 Imazu-naka, Tsurumi-ku, Osaka, 538-0042, Japan

SO Chemical & Pharmaceutical Bulletin (2007), 55(12), 1682-1688
CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The authors developed new i.v. sedative-hypnotic compds. with the isoindolin-1-one skeleton focusing on the water-soluble property and in vivo safety. The authors synthesized approx. 170 derivs. and evaluated their hypnotic effects by i.v. administration of the compds. to mice. A series of the 2-phenyl-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]isoindolin-1-one analogs (I-IV) showed potent sedative-hypnotic activity with good water solubility and a wide safety margin. The hypnotic doses (HD50s) of these 4 compds. when administered to mice were 2.35, 1.90, 2.17, and 3.12 mg/kg, resp., and the LDs (LD50s) were 88.67, 64.69, >120, and >120 mg/kg, resp. The therapeutic indexes (LD50/HD50) were 37.73, 34.05, >55.30, and >38.46, resp. Among these IV is being considered as the most potential candidate for clin. trials in humans.

IT 701304-01-0P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(isoindolin-1-one derivs. as water-soluble sedative-hypnotic agents)

IT 701304-02-1P 701304-03-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(isoindolin-1-one derivs. as water-soluble sedative-hypnotic agents)

IT 701304-01-0P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(isoindolin-1-one derivs. as water-soluble sedative-hypnotic agents)

RN 701304-01-0 HCAPLUS

CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
25° for 16 h to give 5,6-dimethyl-2-(3-fluorophenyl)-3-[[(4-methyl-1-piperazinyl)carbonyl]methyl]isoindolin-1-one. 5,6-Dimethyl-2-(4-fluorophenyl)-3-[[(4-methyl-1-piperazinyl)carbonyl]methyl]isoindolin-1-one monohydrochloride (II) showed analgesic effect on mice at 30 mg/kg p.o. in 5 min after administration and required lower dosage than gabapentin. (-)-II stereoisomer was active but (+)-II stereoisomer was inactive. A tablet formulation contg. II was described.

IT 701304-01-0P 701304-04-3P 701304-06-5P
RL: PAC (Pharmacological activity), SPN (Synthetic preparation); THU (Therapeutic use), BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic pain control agent compns. containing them)

IT 701304-01-0P
RL: PAC (Pharmacological activity), SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic pain control agent compns. containing them)

RN 701304-01-0 HCAPLUS

CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1261054 HCAPLUS

DN 144:6817

TI Preparation of 2-phenyl-2,3-dihydroisoindolin-1-one derivatives and neurogenic pain control agent compositions containing them

IN Yoshimura, Masakazu; Kanamitsu, Norimasa, Itsuji, Yutaka; Osaki, Takashi; Kawashima, Motoko

PA Maruishi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2005113501	A1	20051201	2005WO-JP0009361	20050523
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2005245292	A1	20051201	2005AU-000245292	20050523
	CA-----2563968	A1	20051201	2005CA-002563968	20050523
	EP-----1749817	A1	20070207	2005EP-000741421	20050523
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
	CN-----1956955	A	20070502	2005CN-080016837	20050523
	BR--2005011546	A	20080102	2005BR-000011546	20050523
	NO--2006004868	A	20070226	2006NO-000004868	20061025
	IN-2006DN06250	A	20071130	2006IN-DN0006250	20061025
	KR--2007018077	A	20070213	2006KR-000724401	20061121
	MX-2006PA13766	A	20070208	2006MX-PA0013766	20061124
	US-20080021042	A1	20080124	2007US-000587367	20070717
PRAI	2004JP-000153206	A	20040524		
	2005WO-JP0009361	W	20050523		

OS MARPAT 144:6817

GI



AB A neurogenic pain control agent composition containing either a compound represented by the formula (I) [R1, R2 = C1-6 alkyl or R1 and R2 are bonded together to form OCH2O, (CH2)3, CH2OCH2, or a 6-membered condensed ring containing conjugated double bond; X = halo, C1-6 alkoxy or X together with Ph group to which X is bonded form 3,4-methylenedioxyphenyl; m = an integer of 0-2, Y = Q, COR4, cyclopropylmethyl, piperidin-1-yl; wherein R4 = C1-4 alkyl; X = O, S] or a salt thereof is disclosed. The compds. I possess fast analgesic activity against neuropathic pains without affecting motor function. Thus, 2-[2-(3-fluorophenyl)-5,6-dimethyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl]acetic acid 0.50, 1-methylpiperazine 0.16, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 0.31, 1-hydroxybenzotriazole hydrate 0.25 g were stirred in 40 mL THF at

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:467859 HCAPLUS

DN 141:38525

TI Preparation of isoindoline derivatives as narcotic drugs

IN Toyooka, Kouhei; Kanamitsu, Norimasa; Yoshimura, Masakazu; Kuriyama, Haruo; Tamura, Takashi

PA Maruishi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004048332	A1	20040610	2003WO-JP0014986	20031125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, DM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, RE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA-----2505029	A1	20040610	2003CA-002505029	20031125
	AU--2003284669	A1	20040618	2003AU-000284669	20031125
	JP--2004189733	A	20040708	2003JP-000393809	20031125
	EP-----1566378	A1	20050824	2003EP-000774195	20031125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR--2003016645	A	20051011	2003BR-000016645	20031125
	CN-----1741995	A	20060301	2003CN-080109189	20031125
	NZ------539834	A	20070831	2003NZ-000539834	20031125
	IN-2005DN01967	A	20070713	2005IN-DN0001967	20050509
	US-20060052392	A1	20060309	2005US-000534414	20050511
	NO--2005002529	A	20050623	2005NO-000002529	20050526
PRAI	2002JP-000342399	A	20021126		
	2003WO-JP0014986	W	20031125		

OS MARPAT 141:38525

GI



AB The title compds. I [wherein R1 = 1 to 3 alkyl or alkoxy, or a ring attached to benzene ring; X = O or S; R2 = (un)substituted Ph, PhCH2, pyridyl, etc.; L = (un)substituted -(CH2)n-H, -N(CH2CH2)2N-H, OH, etc., n = 1-8, with provisos] or salts thereof are prepared as narcotic drugs. For example, the compound II•HCl was prepared in a multi-step synthesis. Some of I showed strong sedative activity in rat

IT 701304-01-0P 701304-02-1P 701304-03-2P
701304-04-3P 701304-05-4P 701304-06-5P
701304-22-5P 701304-23-6P 701304-24-7P
701304-25-8P 701304-26-9P 701304-27-0P
701304-32-7P
RL: PAC (Pharmacological activity), SPN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES

L14 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Uses)
(drug candidate; prepn. of isoindoline derivs. as narcotic drugs)
IT 913304-11-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of isoindoline derivs. as narcotic drugs)
RN 913304-11-0 HCAPLUS
CN 2propoxy[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[3-(4-methyl-1-piperazinyl)-1-oxopropyl]- (CA INDEX NAME)



RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr l19 tot

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:128596 HCAPLUS
DN 148:369264
TI Novel water-soluble sedative-hypnotic agents: isoindolin-1-one derivatives
AU Kanamitsu, Norimasa; Osaki, Takashi; Itsuji, Yutaka; Yoshimura, Masakazu; Tsujimoto, Hisashi; Soga, Manabu
CS Central Research Laboratory, Maruishi Pharmaceutical Co., Ltd., 2-2-18 Imazu-naka, Tsurumi-ku, Osaka, 538-0042, Japan
SO Chemical & Pharmaceutical Bulletin (2007), 55(12), 1682-1688
CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The authors developed new i.v. sedative-hypnotic compds. with the isoindolin-1-one skeleton focusing on the water-soluble property and in vivo safety. The authors synthesized approx. 170 derivs. and evaluated their hypnotic effects by i.v. administration of the compds. to mice. A series of the 2-phenyl-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]isoindolin-1-one analogs (I-IV) showed potent sedative-hypnotic activity with good water solubility and a wide safety margin. The hypnotic doses (HD50s) of these 4 compds. when administered to mice were 2.35, 1.90, 2.17, and 3.12 mg/kg, resp., and the LDs (LD50s) were 88.67, 64.69, >120, and >120 mg/kg, resp. The therapeutic indexes (LD50/HD50) were 37.73, 34.05, >55.30, and >38.46, resp. Among these IV is being considered as the most potential candidate for clin. trials in humans.
IT 870234-68-7P 1013427-48-9P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(isoindolin-1-one derivs. as water-soluble sedative-hypnotic agents)
RN 870234-68-7 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 1013427-48-9 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-2-phenyl-, (-)- (CA INDEX NAME)

Rotation (-).

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:268409 HCAPLUS
DN 144:312115
TI Preparation of 3-(piperazinylcarbonylmethyl)isoindole derivatives and anesthetic and sedative compositions containing them
IN Kanemitsu, Norimasa; Itsuji, Hiroshi; Osaki, Takashi; Tsujimoto, Hisashi; Inoue, Keiji
PA Maruishi Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP--2006076913	A	20060323	2004JP-000262082	20040909
PRAI	2004JP-000262082		20040909		

OS MARPAT 144:312115
GI



I

AB Claimed are the derivs. I (R1 = Me, 2 R1 groups are bonded to form C2-4 alkylene, R2 = OH, C1-5 saturated aliphatic hydrocarbyl or C3-6 unsatd. hydrocarbyl substituted with C1-3 alkoxy or oxo; X = H, halo) and their salts. The compns. containing I (salts) and carriers are also claimed. The compns. are used by i.v. dosing for induction and maintenance of general anesthesia, management of sedation after operation or in intensive care, etc. Thus, 5,6-indandicarboxylic anhydride (preparation given) was reacted with 3-FC6H4NH2 in AcOH at 135° for 3 h to give 2-(3-fluorophenyl)-6,7-dihydrocyclopenta[f]isoindole-1,3(2H,5H)-dione, which was reduced and the resulting 2-(3-fluorophenyl)-3-hydroxy-3,5,6,7-tetrahydrocyclopenta[f]isoindol-1(2H)-one was reacted with (carboethoxymethylene)triphenylphosphorane to give 2-[2-(3-fluorophenyl)-3-oxo-1,2,3,5,6,7-hexahydrocyclopenta[f]isoindol-1-yl]acetic acid. This was resolved via diastereomeric salt formation with (S)-(-)-phenylethylamine and the (-)-isomer (0.15 g) was amidated with 1-(2-methyl-2-propenyl)piperazine to give 0.15 g (-)-I [R1R1 = (CH2)3, R2 = CH2CMe:CH2, X = 3-F]. Similarly prepared (-)-I.HCl [R1R2 = (CH2)3, R2 = CH2CH:CH2, X = 3-F] showed anesthetic activity with HD50 (min. dose to induce ≥30 s loss of righting reflex in 50% mice) of 1.74 mg/kg, vs. 14.72 mg/kg of propofol.
IT 879895-96-2P 879895-97-3P 879895-98-4P
879895-99-5P 879896-00-1P 879896-01-2P
879896-02-3P 879896-03-4P 879896-04-5P
879896-05-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (piperazinylcarbonylmethyl)isoindole derivs. and i.v. anesthetic and sedative compns. containing them)
RN 879895-96-2 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-[4-(2-methyl-2-propen-1-yl)-1-piperazinyl]-2-oxoethyl]-, (-)- (CA INDEX NAME)

Rotation (-).

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 879895-97-3 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propen-1-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).



RN 879895-98-4 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propen-1-yl)-1-piperazinyl]ethyl]-2-phenyl-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-)



RN 879895-99-5 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propyn-1-yl)-1-piperazinyl]ethyl]-, (-)- (CA INDEX NAME)

Rotation (-).

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 879896-00-1 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propyn-1-yl)-1-piperazinyl]ethyl]-2-phenyl-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-)



● HCl

RN 879896-01-2 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-[4-(2-methoxyethyl)-1-piperazinyl]-2-oxoethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-)



● HCl

RN 879896-02-3 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxoethyl]-, hydrochloride (1:1), (-)-

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)

Rotation (-)



● HCl

RN 879896-03-4 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-oxopropyl)-1-piperazinyl]ethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-)



● HCl

RN 879896-04-5 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3-[2-[4-(2,2-dimethoxyethyl)-1-piperazinyl]-2-oxoethyl]-2-(3-fluorophenyl)-3,5,6,7-tetrahydro-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 879896-05-6 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-[4-(2-methyl-2-propen-1-yl)-1-piperazinyl]-2-oxoethyl]-2-phenyl-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).



● HCl

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1261054 HCAPLUS
DN 144:6817
TI Preparation of 2-phenyl-2,3-dihydroisoindolin-1-one derivatives and neurogenic pain control agent compositions containing them
IN Yoshimura, Masakazu; Kanamitsu, Norimasa, Itsuji, Yutaka, Osaki, Takashi; Kawashima, Motoko
PA Maruishi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2005113501	A1	20051201	2005WO-JP0009361	20050523
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, DM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2005245292	A1	20051201	2005AU-000245292	20050523
	CA-----2563968	A1	20051201	2005CA-002563968	20050523
	EP-----1749817	A1	20070207	2005EP-000741421	20050523
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
	CN-----1956955	A	20070502	2005CN-080016837	20050523
	BR--2005011546	A	20080102	2005BR-000011546	20050523
	NO--2006004868	A	20070226	2006NO-000004868	20061025
	IN-2006DN06250	A	20071130	2006IN-DN0006250	20061025
	KR--2007018077	A	20070213	2006KR-000724401	20061121
	MX-2006PA13766	A	20070208	2006MX-PA0013766	20061124
	US-20080021042	A1	20080124	2007US-000587367	20070717
PRAI	2004JP-000153206	A	20040524		
	2005WO-JP0009361	W	20050523		

OS MARPAT 144:6817
GI



AB A neurogenic pain control agent composition containing either a compound represented by the formula (I) [R1, R2 = C1-6 alkyl or R1 and R2 are bonded together to form OCH2O, (CH2)3, CH2OCH2, or a 6-membered condensed ring containing conjugated double bond; X = halo, C1-6 alkoxy or X together with Ph group to which X is bonded form 3,4-methylenedioxyphenyl, m = an integer of 0-2, Y = Q, COR4, cyclopropylmethyl, piperidin-1-yl, wherein R4 = C1-4 alkyl, X = O, S] or a salt thereof is disclosed. The compds. I possess fast analgesic activity against neuropathic pains without affecting motor function. Thus, 2-[2-(3-fluorophenyl)-5,6-dimethyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl]acetic acid 0.50, 1-methylpiperazine 0.16, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 0.31, 1-hydroxybenzotriazole hydrate 0.25 g were stirred in 40 mL THF at 25° for 16 h to give 5,6-dimethyl-2-(3-fluorophenyl)-3-[[(4-methyl-1-piperazinyl)carbonyl]methyl]isoindolin-1-one. 5,6-Dimethyl-2-(4-fluorophenyl)-3-[[(4-methyl-1-piperazinyl)carbonyl]methyl]isoindolin-1-one monohydrochloride (II) showed analgesic effect on mice at 30 mg/kg p.o. in

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
5 min after administration and required lower dosage than gabapentin (-)-II stereoisomer was active but (+)-II stereoisomer was inactive. A tablet formulation contg. II was described.

IT 870171-13-4P 870171-15-6P 870171-17-8P
870171-19-0P 870171-21-4P 870171-23-6P
870171-25-8P 870171-30-5P 870171-32-7P
870171-34-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic pain control agent compns. containing them)

RN 870171-13-4 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, hydrochloride (1:1), (-)- (CA INDEX NAME)

Rotation (-).



RN 870171-15-6 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propen-1-yl)-1-piperazinyl]ethyl]-2-phenyl-, (-)- (CA INDEX NAME)

Rotation (-)



RN 870171-17-8 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propyn-1-yl)-1-piperazinyl]ethyl]-2-phenyl-, (-)- (CA INDEX NAME)

Rotation (-).

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 870171-19-0 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3-[2-[4-(cyclopropylmethyl)-1-piperazinyl]-2-oxoethyl]-3,5,6,7-tetrahydro-2-phenyl-, (-)- (CA INDEX NAME)

Rotation (-).



RN 870171-21-4 HCAPLUS
CN 5H-1,3-Dioxolo[4,5-f]isoindol-5-one, 6,7-dihydro-7-[2-oxo-2-[4-(2-propen-1-yl)-1-piperazinyl]ethyl]-6-phenyl- (CA INDEX NAME)



RN 870171-23-6 HCAPLUS
CN 5H-Furo[3,4-f]isoindol-5-one, 1,3,6,7-tetrahydro-7-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-6-phenyl- (CA INDEX NAME)



RN 870171-25-8 HCAPLUS
CN 5H-Furo[3,4-f]isoindol-5-one, 1,3,6,7-tetrahydro-7-[2-oxo-2-[4-(2-propen-1-yl)-1-piperazinyl]ethyl]-6-phenyl- (CA INDEX NAME)



L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 870171-30-5 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propen-1-yl)-1-piperazinyl]ethyl]-2-phenyl- (CA INDEX NAME)



RN 870171-32-7 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3,5,6,7-tetrahydro-3-[2-oxo-2-[4-(2-propyn-1-yl)-1-piperazinyl]ethyl]-2-phenyl- (CA INDEX NAME)



RN 870171-34-9 HCAPLUS
CN Cyclopent[f]isoindol-1(2H)-one, 3-[2-[4-(cyclopropylmethyl)-1-piperazinyl]-2-oxoethyl]-3,5,6,7-tetrahydro-2-phenyl- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
-> b uspatall
FILE 'USPATFULL' ENTERED AT 11:19:45 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 11:19:45 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:19:45 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

-> d bib abs hitrn fhitstr 120 tot
```

```
L20  ANSWER 1 OF 2  USPATFULL on STN
AN      2008:23861  USPATFULL
TI      Composition For Controlling Neuropathic Pain
IN      Masakazu, Yoshimura, Kobe-shi, Hyogo, JAPAN
PA      MARUISHI PHARMACEUTICAL CO., LTD., Osaka-shi, Osaka, JAPAN, 541-0044
        (non-U.S. corporation)
PI      US-20080021042       A1  20080124
AI      2005US-000587367     A1  20050523 (11)
        2005WO-JP0009361         20050523
                                 20070717  PCT 371 date
PRAI    2004JP-000153206     20040524
DT      Utility
FS      APPLICATION
LREP    HAMRE, SCHUMANN, MUELLER & LARSON, P.C., P.O. BOX 2902, MINNEAPOLIS, MN,
        55402-0902, US
CLMN    Number of Claims: 15
ECL     Exemplary Claim: 1-11
DRWN    8 Drawing Page(s)
LN.CNT 860
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The instant application provides a pharmaceutical composition for
        controlling neuropathic pain, which comprises a compound of formula:
        ##STR1##  or a salt thereof

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT    701304-01-0P 701304-04-3P 701304-06-5P
       870171-13-4P 870171-15-6P 870171-17-8P
       870171-19-0P 870171-21-4P 870171-23-6P
       870171-25-8P 870171-30-5P 870171-32-7P
       870171-34-9P
         (preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic
         pain control agent compns. containing them)
IT   701304-01-0P
         (preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic
         pain control agent compns. containing them)
RN    701304-01-0  USPATFULL
CN    Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-
        (4-methyl-1-piperazinyl)-2-oxoethyl]-  (CA INDEX NAME)
```




```
L20  ANSWER 2 OF 2  USPATFULL on STN
AN      2006:61222  USPATFULL
TI      Isoindoline derivative
IN      Toyooka, Kouhei, Osaka-fu, JAPAN
        Kanamitsu, Norimasa, Takarazuka-shi, JAPAN
        Yoshimura, Masakazu, Hyogo-ken, JAPAN
        Kuriyama, Haruo, Osaka-fu, JAPAN
        Tamura, Takashi, Osaka-fu, JAPAN
PA      MARUISHI PHARMACEUTICAL CO., LTD (non-U.S. corporation)
PI      US-20060052392       A1  20060309
AI      2003US-000534414     A1  20031125 (10)
        2003WO-JP0014986         20031125
                                 20050511  PCT 371 date
PRAI    2002JP-000342399     20021126
DT      Utility
FS      APPLICATION
LREP    FOLEY AND LARDNER LLP, SUITE 500, 3000 K STREET NW, WASHINGTON, DC,
        20007, US
CLMN    Number of Claims: 16
ECL     Exemplary Claim: 1
DRWN    No Drawings
LN.CNT 1971
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Provided is a novel isoindoline compound of the formula (I).    ##STR1##
        The compound is useful for anesthesia by inducing sedation in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT    701304-01-0P 701304-02-1P 701304-03-2P
       701304-04-3P 701304-05-4P 701304-06-5P
       701304-22-5P 701304-23-6P 701304-24-7P
       701304-25-8P 701304-26-9P 701304-27-0P
       701304-32-7P
         (drug candidate; preparation of isoindoline derivs. as narcotic drugs)
IT   701304-01-0P
         (drug candidate; preparation of isoindoline derivs. as narcotic drugs)
RN    701304-01-0  USPATFULL
CN    Cyclopent[f]isoindol-1(2H)-one, 2-(3-fluorophenyl)-3,5,6,7-tetrahydro-3-[2-
        (4-methyl-1-piperazinyl)-2-oxoethyl]-  (CA INDEX NAME)
```



```
=> d his

     (FILE 'HOME' ENTERED AT 10:46:28 ON 15 SEP 2008)

     FILE 'HCAPLUS' ENTERED AT 10:46:39 ON 15 SEP 2008
L1             1 US20060052392 /PN

     FILE 'REGISTRY' ENTERED AT 10:47:02 ON 15 SEP 2008

     FILE 'HCAPLUS' ENTERED AT 10:47:02 ON 15 SEP 2008
L2             TRA L1 1- RN :      284 TERMS

     FILE 'REGISTRY' ENTERED AT 10:47:03 ON 15 SEP 2008
L3           284 SEA L2
L4           254 L3 AND NRS>=2
L5            17 L4 AND NRRS>=3
                 SAV TEM J414C4/A L***
L6               STR L***
L7               STR L***
L8            32 L7
L9          9009 L7 FULL
                 SAV TEM J414C4/A L9
L10           17 L9 AND L3
L11           13 L10 AND NC2NC2/ES
L12         8992 L9 NOT L10-11
L13              STR L6
L14              0 L13 SAM SUB=L9
L15           42 L13 FULL SUB=L9
L16           13 L15 AND L3
L17           29 L15 NOT L16

     FILE 'HCAPLUS' ENTERED AT 11:18:03 ON 15 SEP 2008
L18            3 L16
L19            3 L17

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:18:10 ON 15 SEP 2008
L20            2 L16-17

     FILE 'HCAOLD' ENTERED AT 11:18:38 ON 15 SEP 2008
L21            0 L16
L22            0 L17

=>
```